BASF and Biomillenia join forces in microbiome research to promote healthy skin
Research aims to identify novel dermocosmetic active ingredients via unique microbiome-on-a-chip technology.
BASF and Biomillenia have signed a microbiome discovery agreement, which aims to identify novel dermocosmetic active ingredients involved in promoting skin health.
The French company Biomillenia will contribute its unique microbiome-on-a-chip technology that has the ability to grow specific microbes and maintain a higher diversity of living microbes than with standard microbiology methods. It will allow BASF to explore how active ingredients can modulate the presence and growth of the skin microbiota, and consequently affect its health. By bringing together interdisciplinary know-how from within the company as well as from external partners, BASF constantly expands its activities dedicated to developing solutions acting on or through the skin microbiota. “The skin hosts a huge and varied microbiota and as such plays an important role in skin health. Biomillenia’s ability to rapidly identify novel microbes and screen for active ingredients involved in promoting healthy skin will enable new research possibilities and market opportunities for BASF,” said David Hérault, R&D Global Director of BASF Beauty Care Solutions. “The microbiome is a vast natural pool of mostly undiscovered microbes that can be leveraged across several industries, including consumer health, agriculture, animal health and food. We are supporting companies in these sectors by providing access to our technology platform to culture and perform functional analysis of microbes in low volume droplets using proprietary lab-on-a-chip technology. In addition, our customers can gain access to our microbial culture collection and state of the art microbe isolation and sequencing technologies,” said Dirk Loeffert, Ph.D., CEO of Biomillenia.
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.